-
Mashup Score: 0
Treatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survival compared with neoadjuvant chemotherapy alone in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Treatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survival compared with neoadjuvant chemotherapy alone in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with IMNN-001 plus neoadjuvant platinum chemotherapy led to an improvement in PFS vs neoadjuvant chemotherapy alone in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. #ovca #oncology https://t.co/wFT7ESe67p
-
-
Mashup Score: 0Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study - 8 month(s) ago
Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Whitney S. Graybill, MD, MS, presents data from the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in advanced ovarian cancer. #oncology #ovca https://t.co/UATO8z2lnx
-
-
Mashup Score: 0
Treatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survival compared with neoadjuvant chemotherapy alone in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
IMNN-001 Plus Neoadjuvant Chemotherapy Improves PFS in Advanced Ovarian Cancer #ovca #oncology https://t.co/wFT7ESdyhR
-
-
Mashup Score: 0HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations - 8 month(s) ago
Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
WATCH: Experts discuss the biological mechanisms behind HRD in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic. #gyncsm #ovca https://t.co/UPsVLetLep
-
-
Mashup Score: 0Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive Recurrent Ovarian Cancer - 8 month(s) ago
The addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival benefit among patients with recurrent epithelial ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Atezolizumab + bevacizumab & platinum-based chemotherapy did not result in a statistically significant PFS benefit among patients with recurrent epithelial ovarian cancer. #ovca #oncology https://t.co/5uw7cdj9bi
-
-
Mashup Score: 0Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive Recurrent Ovarian Cancer - 8 month(s) ago
The addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival benefit among patients with recurrent epithelial ovarian cancer.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The phase 3 ATALANTE trial did not meet its coprimary end points of investigator-assessed PFS in the intention-to-treat and PD-L1–positive populations of patients with platinum-sensitive ovarian cancer. @JCO_ASCO #ovca #oncology https://t.co/5uw7cdj9bi https://t.co/xRSMp7le4P
-
-
Mashup Score: 0ADC Advances and Updated PARP Indications Support Focus on Individualized Approaches in Ovarian Cancer - 8 month(s) ago
Heather R. Williams, MD, expands on updated data from the the phase 3 PRIMA trial initially supporting the use of frontline PARP inhibitor maintenance in ovarian cancer, as well as changing indications for niraparib based on data from the NOVA trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Changes to the use of PARP inhibitors in platinum-sensitive ovarian cancer, alongside encouraging results with emerging ADCs, are shifting treatment approaches across ovarian cancer subtypes. @HeatherReneeWi1 @uamscancer #ovca https://t.co/ZAZPEHnocQ https://t.co/Qlizymdz14
-
-
Mashup Score: 0
The well-publicized severe shortage of vitally important generic antineoplastic agents has highlighted a serious misalignment in the existing market-based and regulatory environment that permitted such an extraordinary situation to develop without meaningful.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ensuring the availability of well-established, relatively inexpensive but currently less-profitable generic antineoplastic drugs remains a clinically relevant goal in oncology. @DrMaurieMarkman @cityofhope #ovca #oncology https://t.co/eAvcu94YQB https://t.co/f75gijsQfn
-
-
Mashup Score: 0ADC Advances and Updated PARP Indications Support Focus on Individualized Approaches in Ovarian Cancer - 8 month(s) ago
Heather R. Williams, MD, expands on updated data from the the phase 3 PRIMA trial initially supporting the use of frontline PARP inhibitor maintenance in ovarian cancer, as well as changing indications for niraparib based on data from the NOVA trial.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Heather R. Williams, MD, discusses changing indications for niraparib in ovarian cancer based on data from the NOVA trial. @HeatherReneeWi1 @uamscancer #ovca https://t.co/utBeBhsX3f
-
Interim data from the phase 1/2 OVATION 2 trial showed that treatment with IMNN-001 and neoadjuvant chemotherapy was associated with an approximate 33% delay in disease progression vs neoadjuvant chemotherapy alone. #ovca #oncology https://t.co/wFT7ESe67p https://t.co/NHNwekF2aN